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G2A is an orphan G protein-coupled receptor (GPCR), expressed
predominantly in T and B cells and homologous to a small group
of GPCRs of unknown function expressed in lymphoid tissues.
G2A is transcriptionally induced in response to diverse stimuli,
and its ectopic expression suppresses transformation of B lym-
phoid precursors by BCR-ABL. G2A induces morphological trans-
formation of NIH 3T3 fibroblasts. Microinjection of constructs
encoding G2A into Swiss 3T3 fibroblasts induces actin reorga-
nization into stress fibers that depends on RhoA, but not CDC42
or RAC. G2A elicits RhoA-dependent transcriptional activation of
serum response factor. Direct evaluation of RhoA activity dem-
onstrates elevated levels of RhoA-GTP in G2A-expressing cells.
Microinjection of embryonic fibroblasts derived from various Ga
knockout mice establishes a requirement for Ga13 but not Ga12
or Gaqy11 in G2A-induced actin rearrangement. In conclusion,
G2A represents a family of GPCRs expressed in lymphocytes that
may link diverse stimuli to cytoskeletal reorganization and
transcriptional activation through a pathway involving Ga13
and RhoA.
The seven transmembrane spanning G protein-coupled re-ceptors (GPCRs) constitute the largest family of cell-surface
receptors, controlling diverse biological processes. Ligand bind-
ing to GPCRs elicits activation of signaling pathways via asso-
ciated heterotrimeric G proteins comprising a, b, and g subunits.
Both GTP-bound a and free bg components mediate signaling
events through their interaction with effector molecules, leading
to an appropriate physiological response. Biologicalybiochemi-
cal responses to activation of a GPCR are determined primarily
by the nature of the Ga subunits to which it is coupled, and this
property cannot be predicted by primary sequence analysis of
newly discovered GPCRs (1). A key objective in the study of an
orphan GPCR is to define its Ga coupling profile. Direct
experimental approaches such as photolabeling of Ga subunits
with radiolabeled GTP analogues (2) are limited in their appli-
cation to the study of GPCRs in the absence of a defined
ligandyagonist. However, signaling events downstream of many
Ga subunits are well defined, and their analysis can serve as
surrogate assays of Ga coupling profiles. Indeed, the biochem-
icalysignaling properties of GPCRs are most often recapitulated
in heterologous cell types (3, 4), and cell lines in which the
spectrum of expressed Ga subunits are defined can serve as
systems in which to study the primary signal transduction and
biological characteristics of orphan GPCRs (5).
We previously have reported the identification of a novel
GPCR, G2A, expressed predominantly in B and T lymphoid cells
(6). G2A is homologous to a small number of orphan GPCRs of
unknown function expressed in lymphoid tissues, among which
TDAG8 is most closely related (7). The genes encoding G2A and
TDAG8 both map to chromosome 14q 31–32.1, a region in which
abnormalities frequently are found in T cell leukemias and
lymphomas (6, 8).
G2A is transcriptionally induced in B lymphocytes after
antigen receptor crosslinking and in pre-B lymphocytes by the
BCR-ABL tyrosine kinase oncogene. Interestingly, although
transcriptional induction of G2A is associated with proliferative
responses, its ectopic expression inhibits transformation of B cell
precursors by BCR-ABL (6). We addressed the question of what
mechanisms are involved in these biological effects by conduct-
ing studies aimed at defining signal transduction events down-
stream of G2A and their Ga specificity.
In light of our previous observations demonstrating that
ectopic expression of G2A is counterselected in fibroblasts and
B lymphoid precursors (6), an experimental approach was used
in which the potential for biological selection was avoided.
Transient biochemical assays and microinjection of constructs
encoding G2A into Swiss 3T3 fibroblasts and embryonic
fibroblasts derived from Ga knockout mice (Ga KO MEFs)
delineate a signaling pathway downstream of G2A to RhoA
activation via Ga13 leading to actin rearrangement and serum
response factor (SRF)-dependent transcriptional activation.
Taken together, these observations suggest that G2A expres-
sion and transcriptional induction may play a role in the
integration of proliferative andyor differentiative signals with
cytoskeletal reorganization.
Materials and Methods
Materials. Rhodamine-conjugated phalloidin and antivinculin
mAb (VIN-11–5) were from Sigma. Aminomethylcoumarin-
conjugated secondary anti-rabbit antibody was from Jackson
ImmunoResearch. All other fluorescently conjugated secondary
antibodies were from PharMingen. Anti-RhoA mAb was from
Santa Cruz Biotechnology. Anti-Ga13 polyclonal antibody (AS
343) was provided by Karsten Spicher (Benjamin Franklin
University, Berlin).
Cell Lines and Plasmids. Wild-type and Ga KO MEFs were
prepared and cultured from embryonic day 8.5 to 9.5 embryos
as described (9). Swiss 3T3, NIH 3T3, 293T and Ga KO
MEFs (Ga13 KO, ref. 9; Gaqy11 KO, ref. 10; and Ga12 KO,
M.I.S., unpublished work) were cultured in DMEMy10% FCS.
Abbreviations: GPCR, G protein-coupled receptor; KO, knockout; MEF, mouse embryonic
fibroblast; SRF, serum response factor; GFP, green fluorescent protein; MSCV, murine stem
cell virus.
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293T cells were transfected by the calcium phosphate precip-
itation technique. The glutathione S-transferase-rhotekin Rho
binding domain construct was provided by Martin Schwartz
(The Scripps Research Institute, La Jolla, CA). pEXV3 V12
RAS, N19 RhoA, N17 CDC42, and N17 RAC constructs were
provided by Chris Marshall (Institute of Cancer Research,
London). pRK5 mycC3T was provided by Alan Hall (Univer-
sity College, London).
Microinjection and Immunocytochemical Staining. Cells for micro-
injection were plated at a density of 104yml onto 13-mm
acid-washed glass coverslips. Two days later, cells were serum
starved for 16 h. Plasmids in 50 mM Hepes (pH 7.4), 40 mM
NaCl were injected into nuclei by using an Ependorf semiau-
tomated injector assembled on an inverted Zeiss Axiovert 10
microscope. Approximately 200–250 cells were microinjected
on each coverslip and returned to the incubator for an
additional 4 h or as indicated. Coverslips subsequently were
rinsed once in PBS and fixed in 4% paraformaldehydeyPBS for
10 min at room temperature. Coverslips were washed in PBS
and permeabilized by incubation with PBS, 0.2% Triton X-100
for 5 min at room temperature before incubation with 1:100
Ga13 antiserum, 1:100 9E10 mAb, or 1:100 antivinculin mAb
in PBS, 0.15% Triton X-100, 25 mgyml BSA at room temper-
ature for 1 h in a humidified chamber. Coverslips were washed
four times in PBS and incubated with rhodamine-conjugated
goat anti-mouse secondary antibody (for vinculin), amino-
methylcoumarin-conjugated goat anti-mouse secondary anti-
body (for MYC epitope-tagged Rho family GTPases), or
aminomethylcoumarin-conjugated goat anti-rabbit secondary
antibody (for Ga13) at 1:100 for 1 h at room temperature in
a humidified chamber. Where appropriate, 0.2 mgyml rhoda-
mine-conjugated phalloidin also was included. Coverslips were
washed four times in PBS followed by one wash in H2O and
mounted by inversion onto 5 ml Gelvatol mountant. Cells were
examined on a Zeiss axiophot microscope with a Zeiss 40 3 1.3
oil immersion objective. In all experiments, more than 90% of
injected cells exhibited the described response.
SRF Luciferase Assays. NIH 3T3 cells were cotransfected with 0.2
mg of the reporter plasmid pSRF-firefly luciferase (Stratagene),
0.2 mg of pTK-Renilla luciferase (Promega), and 0.3 mg of
pEXV3 G2A or 0.3 mg of pEXV3 green fluorescent protein
(GFP), plus 0.2 mg pRK5 mycC3T or 0.2 mg pEXV3 GFP
(totaling 0.9 mg DNA) by the Superfect system (Life Technol-
ogies, Gaithersburg, MD). Twenty four hours later, cells were
harvested, washed with PBS, and lysed in 200 ml of Passive Lysis
Buffer (Promega). Firefly and Renilla luciferase values were
obtained by analyzing 10 ml of lysate according to the standard
protocol provided in the Dual Luciferase Assay Kit (Promega)
in a Lumat LB 9501 luminometer (10-s count). Relative lucif-
erase activity is represented as (firefly luciferase valueyRenilla
luciferase value) 3 1022.
Results
G2A Induces Morphological Alterations in Fibroblasts. Dramatic
morphological alterations, including suppression of contact
inhibition and reduced spreading, are readily apparent in NIH
3T3 fibroblasts less than 48 h after their infection with
G2A-encoding retroviruses (Fig. 1A). G2A-expressing cells in
subconf luent cultures appear elongated and tightly packed,
with a significantly greater proportion detached and rounded.
These morphological changes are quite distinct from those
induced after infection with retroviruses encoding V12 RAS,
which exhibit a more refractile morphology and focal organi-
zation (Fig. 1 A). Suppression of contact inhibition of growth
is even more apparent in conf luent G2A-expressing cultures,
which form tightly packed foci (Fig. 1B).
We speculated that the morphological changes induced by
G2A may result from deregulation of mechanisms controlling
cytoskeletal architecture. This prompted us to examine the
involvement of Rho family GTPases, which relay signals from
cell surface receptors including GPCRs, receptor tyrosine ki-
nases, and integrins to the actin cytoskeleton (11, 12).
G2A Induces Assembly of Actin Stress Fibers in Swiss 3T3 Cells. To
avoid prolonged expression of G2A during which biological
adaptation and selection may contribute to the cellular pheno-
type, we used microinjection of Swiss 3T3 cells, a system in which
acute regulation of expression is readily achieved in a cell type
whose complement of expressed Ga subunits is known (13).
Initially, G2A encoding constructs to be used in these studies
(pEXV3 G2A and pEXV3 G2A.GFP) were transfected into
293T cells to ensure expression of G2A and G2A.GFP proteins.
Western blotting with affinity-purified rabbit antiserum raised
against carboxyl-terminal sequences of G2A reveals proteins of
expected size (data not shown).
Nuclear microinjection of pEXV3 G2A or pEXV3
G2A.GFP at 10 ngyml into Swiss 3T3 cells elicited the forma-
tion of actin stress fibers and assembly of focal adhesion
complexes (Fig. 2A). A construct encoding a nuclear GFP
protein (pEXV3 GFP) was coinjected at 10 ngyml in all
experiments apart from those performed with G2A.GFP to
identify productively injected cells. In this and all other
experiments, approximately 200–250 cells were microinjected
and all possible microscopic fields were examined. Both G2A
Fig. 1. G2A induces morphological alterations in NIH 3T3 cells. (A) NIH 3T3
cells were infected with the indicated retroviruses and cultured for an
additional 36 h. All populations were more than 90% GFP-positive by FACS
analysis. (B) NIH 3T3 cells infected with the indicated retroviruses were
cultured for 7 days.
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and G2A.GFP consistently induce indistinguishable cytoskel-
etal rearrangements in more than 90% of injected cells with
similar kinetics (time points ranging from 1 h to 12 h after
injection) and at similar concentrations of injected plasmid
(down to 0.2 ngyml). Examination of Swiss 3T3 cells 1 h after
their microinjection with a construct encoding V12 RAS
(pEXV3 V12 RAS) revealed only lamellipodial actin rear-
rangement (Fig. 2B, small arrows) consistent with the involv-
ment of Rac as a key downstream target of RAS signaling (14).
G2A Induced Stress Fiber Assembly Requires RhoA. Microinjection
of constitutively active mutants of RhoA into Swiss 3T3
fibroblasts induces the formation of actin stress fibers and focal
adhesion complexes (15). In addition, RhoA functions as a
downstream component of signaling pathways initiated by
ligand stimulation of the G protein-coupled lysophosphatidic
acid receptor, leading to stress fiber assembly (16). To assess
the requirement for RhoA activity in the induction of stress
fibers by G2A, a construct encoding a MYC epitope-tagged
dominant negative mutant form of RhoA (pEXV3 N19 RhoA)
was coinjected with pEXV3 G2A into Swiss 3T3 cells. Coex-
pression of N19 RhoA inhibits G2A-mediated stress fiber
induction, with injected and noninjected cells demonstrating
indistinguishable cytoskeletal organization (Fig. 3A). This
demonstrates that RhoA signaling is required for the induction
of stress fiber assembly by G2A.
Induction of stress fiber assembly by G2A may be mediated by
the sequential activation of CDC42, Rac, and Rho (17). To
directly address the requirement for CDC42 and Rac activity, a
construct encoding either a MYC epitope-tagged dominant
negative mutant of CDC42 or Rac (pEXV3 N17 CDC42 or
pEXV3 N17 Rac) was coinjected with pEXV3 G2A. Expression
of N17 CDC42 or N17 Rac did not inhibit the assembly of stress
fibers induced by G2A (Fig. 3 B and C). Microinjection of
pEXV3 N17 CDC42 or pEXV3 N17 Rac inhibited Bradykinin-
induced formation of filopodia and platelet-derived growth
factor induced lamellipodial extensions, respectively in over 80%
of injected cells (data not shown).
G2A Activates SRF-Dependent Transcriptional Activation via RhoA. In
addition to their effects on the actin cytoskeleton, Rho family
GTPases regulate transcriptional events. RhoA has been shown
to activate the transcription factor SRF (18), which cooperates
with ternary complex factors in activating transcription at serum
response elements within the promoters of growth factor-
regulated genes such as c-fos (19). We performed transient
transcriptional reporter assays in NIH 3T3 cells in which a
G2A-encoding construct was cotransfected with a reporter
construct comprising the firefly luciferase (Luc) gene driven by
SRF-responsive sequences (SRF-Luc) (18). Normalization for
variability in transfection efficiency was achieved by measuring
the activity of a cotransfected thymidine kinase (TK) promoter-
driven Renilla luciferase construct (pTK-Renilla Luciferase).
Transient expression of G2A induces transcriptional activation
of SRF-Luc, which is inhibited by coexpression of the Rho
inhibitor C3 transferase (Fig. 4A).
G2A Activates RhoA. Limitations associated with the use of the
dominant negative N19 RhoA mutant include its impact on
Fig. 2. (A) Microinjection of G2A induces stress fiber assembly in Swiss 3T3
cells. pEXV3 constructs encoding GFP, G2A.GFP, or G2A plus GFP were micro-
injected into nuclei of serum-starved Swiss 3T3 cells. Four hours later, cells
were fixed and stained with rhodamine-conjugated phalloidin. In addition,
pEXV3 G2A.GFP-injected cells were stained with a monoclonal antibody
against Vinculin to visualize focal adhesion complexes. (B) Serum-starved
Swiss 3T3 cells microinjected with a pEXV3 construct expressing V12 RAS were
processed as in A. (Left) GFP fluorescence. (Right) Phalloidin-stained actin.
Large arrows indicate injected cells. Small arrows in indicate lamellipodia in
pEXV3 V12 RAS-injected cells.
Fig. 3. Induction of stress fiber assembly by G2A is inhibited by N19 RhoA.
Serum-starved Swiss 3T3 cells were microinjected with pEXV3 G2A and pEXV3
GFP plasmids together with pEXV3 constructs encoding (A) MYC epitope-
tagged N19 RhoA, (B) MYC epitope-tagged N17 CDC42, or (C) MYC epitope-
tagged N17 Rac1. Cells were fixed 4 h later and stained with 9E10 mAb to
detect expression of dominant negative Rho family mutants (Middle) and
rhodamine-conjugated phalloidin (Bottom). Large arrows indicate injected
cells. (Bar 5 50 mm.)
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normal cytoskeletal integrity, irrespective of the presence or
absence of a stimulating factor. We therefore used a direct
biochemical approach to assay the activity of RhoA in cellular
lysates obtained from Swiss 3T3 cells 36 h after their infection
with murine stem cell virus (MSCV) GFP or MSCV
G2AiresGFP retroviruses. Briefly, lysates were incubated with a
glutathione S-transferase (GST) fusion protein containing the
RhoA-GTP binding domain of the RhoA effector rhotekin
(GST-RRBD) to affinity precipitate active GTP-bound RhoA as
described (20). Cell populations were more than 90% GFP
positive by FACS analysis before lysis. We observe elevated
levels of RhoA-GTP in Swiss 3T3 cells infected with MSCV
G2AiresGFP compared with that in cells infected with control
MSCV GFP retroviruses (Fig. 4B, lanes 1 and 3). As a control,
incubation with 1 mgyml lysophosphatidic acid for 5 min stim-
ulated an increase in RhoA-GTP levels in both cell populations
(Fig. 4B, lanes 2 and 4). In conclusion, although G2A may signal
through several distinct effectors, we have identified RhoA
activation leading to cytoskeletal rearrangement as a pathway
downstream of G2A.
Induction of Rho-Dependent Cytoskeletal Rearrangement by G2A Is
Mediated by Ga13. One route from GPCRs to RhoA is via
members of the Ga12 class of G proteins, including the ubiq-
uitously expressed Ga12 and Ga13 (21), as well as Gaq (22).
Indeed, microinjection of constitutively active GTPase-deficient
mutants of Ga12 or Ga13 subunits into Swiss 3T3 cells induces
stress fiber assembly (13). More recently, the RGS domain
containing p115 guanine nucleotide exchange factor (p115 GEF)
has been shown to mediate RhoA activation by the Ga12 class
of G proteins (23).
We used MEFs derived from various Ga-deficient mice to
genetically test the involvement of specific G proteins in the
induction of Rho-dependent stress fiber assembly by G2A.
Microinjection of pEXV3 G2A.GFP into wild-type, Gaqy11
KO, and Ga12 KO MEFs elicited stress fiber assembly with
identical frequency and kinetics. However, Ga13 KO and Ga12y
Ga13 KO MEFs did not accumulate abundant stress fibers in
response to microinjection (Fig. 5), demonstrating that G2A
activation of RhoA-dependent actin rearrangement requires
Ga13, not Ga12 or Gaq.
To exclude the possibility that the unresponsiveness of Ga13
KO MEFs to G2A is caused by secondary mutations or epige-
netic changes other than ablation of Ga13 function, Ga13-
deficient fibroblasts were reconstituted with functional Ga13 by
Fig. 4. (A) G2A induces transcriptional activation of SRF. NIH 3T3 cells
were cotransfected with reporter plasmid pSRF-Luc, pTK-Renilla Luc, and
pEXV3 G2A or pEXV3 GFP with or without pRK5 mycC3T (totaling 0.9 mg
DNA). Twenty four hours after transfection, cells were lysed and subjected
to luciferase assays. Transfections and SRF-Luc assays were performed in
triplicate, and results presented are typical of three independent experi-
ments. (B) G2A activates RhoA in Swiss 3T3 cells. Swiss 3T3 cells were
infected with MSCV GFP or MSCV G2AiresGFP retroviruses and 24 h later
were serum-starved for 12 h. Cells subsequently were lysed, and lysates
were incubated on ice for 1 h with glutathione S-transferase-RRBD immo-
bilized on glutathione-agarose beads to affinity precipitate RhoA-GTP.
Affinity precipitates (RhoA GTP) and aliquots of total lysates (total RhoA)
were Western blotted with a mAb against RhoA. Lanes 2 and 4, lysophos-
phatidic acid (LPA) (1 mgyml, 5 min) stimulated activation of RhoA. Lanes
1 and 3, Increased levels of RhoA GTP in G2A expressing Swiss 3T3 cells
compared with control Swiss 3T3 cells.
Fig. 5. G2A-induced stress fiber assembly requires Ga13. The indicated MEFs were microinjected with pEXV3 G2A.GFP, fixed 4 h later, and stained with
rhodamine-conjugated phalloidin. (Upper) GFP fluorescence. (Lower) Phalloidin-stained actin. Arrows indicate injected cells. (Bar 5 50 mm.)
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coinjecting a construct encoding Ga13 (pCIS Ga13). Whereas
microinjection of pCIS Ga13 alone into Ga13 KO MEFs did not
elicit stress fiber assembly (Fig. 6 Left), coinjection of pCIS Ga13
with pEXV3 G2A.GFP induced the formation of abundant actin
stress fibers (Fig. 6 Right). Identical results were obtained with
Ga12yGa13 KO MEFs (data not shown).
We conclude that G2A couples to Ga13, through which G2A
mediates activation of RhoA, leading to cytoskeletal reorgani-
zation and transcriptional activation of SRF.
Discussion
Transcriptional induction of G2A in response to diverse prolif-
erative and genotoxic stimuli together with the impact of its
ectopic expression on cell-cycle progression through G2yM
suggested a possible role of this orphan GPCR in negative
regulatory checkpoint mechanisms in lymphocytes. We now
have extended our studies and demonstrate a direct signaling
pathway from G2A leading to RhoA via Ga13. It recently
was reported that cytoskeletal and morphological alterations
induced by G2A expression in fibroblasts are similar to those
induced by activated mutants of RhoA, Ga12, or Ga13 (24). By
assaying levels of RhoA-GTP in G2A-expressing cells, we have
directly demonstrated activation of RhoA. The role of Ga13 is
established by its requirement for RhoA-dependent cytoskeletal
responses to G2A expression in Ga13 KO MEFs.
Interestingly, a large proportion of the G2A.GFP fusion
protein is localized to the cytoplasm, with a pronounced perinu-
clear pattern suggesting its presence in the endosomal compart-
ment. Although this could simply be the result of its overexpres-
sion, the localization pattern of G2A.GFP is similar to that of an
analogous b2 adrenergic receptor GFP fusion protein (b2AR-
GFP) after agonist stimulation (25). It is possible, therefore, that
G2A is constitutively active when expressed in heterologous cell
types, binds a ligand that is produced intracellularly, or is a ligand
independent receptor subject to continual down-regulatory
modification and internalization. The possibility that a ligand for
G2A may be a small bioactive molecule is strengthened by
certain conserved features shared by G2A and other GPCRs
with this ligand specificity (26).
The well-documented morphological alterations induced in
fibroblasts expressing constitutively activated mutants of RhoA
or Ga13 (27, 28) suggests that deregulation of RhoA activity by
G2A is responsible for its impact on cellular morphology. A role
for RhoA in proliferative control also has been demonstrated in
fibroblasts in the context of oncogenic and mitogenic stimulation
(29–31). Although we do not observe any significant effects of
G2A expression on G13S cell-cycle progression of quiescent
fibroblasts after serum stimulation or in G1-arrested fibroblasts
after removal of a thymidine-induced block (J.H.S.K., L.Q.L.,
and O.N.W., unpublished observations), G2A expression pro-
motes their survival and proliferation in confluent cultures by
overriding contact inhibition of growth.
G2A induces morphological transformation of NIH 3T3 fi-
broblasts yet inhibits transformation of RAT1 fibroblasts to
anchorage independence by BCR-ABL (6). Although these
observations could be reconciled by use of different fibroblastic
lines, G2A also transforms RAT1 fibroblasts to anchorage
independent growth, albeit at a much lower frequency compared
with BCR-ABL (data not shown). It is possible, therefore, that
BCR-ABL and G2A signals in combination may elicit a different
biological outcome to that induced by each in isolation. In this
regard, RAC is implicated as a downstream target of BCR-ABL
(32), and concurrent deregulation of both RAC and RhoA
GTPases may be incompatible with viability or proliferation
(33). This phenomenon also could underlie the suppressive
effect of G2A on B lymphoid transformation by BCR-ABL in
long-term bone marrow cultures, which depend on stromal
contact to sustain B lymphopoiesis.
Inhibition of B lymphoid transformation is the only property
so far ascribed to G2A in a cell type within which it is actually
expressed. Further biological characterization of G2A in lym-
phoid cells is of primary importance, and we have generated
G2A-deficient mice with this objective in mind. A reduction in
latency for leukemogenesis in mice transplanted with BCR-
ABL-infected bone marrow cells from these animals confirms
our previous observations. In addition, a role for G2A in the
regulation of T lymphocyte proliferation has been revealed in
our studies of G2A-deficient mice (L.Q.L., J.H.S.K., and
O.N.W., unpublished observations). In T lymphocytes, RhoA
is implicated in the regulation of T cell antigen receptor
(TCR)ycytoskeleton interaction and sustained TCR-
dependent signaling (34, 35). G2A therefore may play a role in
the regulation of TCR-dependent cytoskeletal rearrangement.
For example, G2A may function in the maintenance of the
immunological synapse after antigen receptoryMHC-peptide
interaction during which segregation of integrin and antigen
receptors into specific areas at cellycell contacts precedes their
reorganization via cytoskeletal mechanisms into clusters me-
diating sustained signaling (36).
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Fig. 6. Reconstitution of functional Ga13 in Ga13 KO MEFs restores their
responsiveness to G2A. Ga13 KO MEFs were microinjected with pEXV3 GFP or
pEXV3 G2A.GFP together with pCIS Ga13, fixed 4 h later, and stained with
rhodamine-conjugated phalloidin (Bottom), and rabbit antiserum against
Ga13 to detect ectopically expressed Ga13 (Middle). (Upper) GFP fluorescence.
Arrows indicate injected cells. (Bar 5 20 mm.)
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